Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Sponsor
Astellas Pharma Inc
Study ID
NCT00892749
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ASP1585 — DRUG
    oral

Study Details

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.

Key Dates

Start date
May 31, 2009
Status verified
Apr 2015
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
248 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1. ASP1585

Primary Outcome Measure

Changes in serum Phosphorus level [ Time Frame: After 48 weeks ]

Related Studies